Beta-Hydroxybutyrate to Boost CAR-T Cell Therapy in Multiple Myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and are scheduled to receive CAR-T cell therapy or a BCMA-directed bispecific antibody treatment
- You are 18 years or older
- You do not have an active infection requiring antibiotics or IV medications
- You have no history of HIV or hepatitis
- You have not lost more than 10% of your body weight in the last 6 weeks
- You are able to carry out light daily activities (ECOG score of 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
This study tests two drugs together to see if they can help people with multiple myeloma that has come back after other treatments. It aims to shrink or control the cancer and may offer a new option for patients who have already tried several therapies.
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.